Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Early reperfusion strategies in tandem with remarkable advances in drugs and devices for
treating myocardial infarction (MI) have contributed to a reduction in early mortality, but
cardiovascular disease remains the leading cause of death worldwide. Current management
strategies cannot solve the problem of cardiomyocyte loss and consequent progression of heart
failure. In this respect, stem-cell therapy has shown potential benefits for repairing the
damaged myocardium. Mesenchymal stem cells (MSCs) have been considered to be attractive
therapeutic candidates because of their high capacity for replication: paracrine effect:
ability to preserve potency: and because they do not cause adverse reactions to allogeneic
versus autologous transplants. Intracoronary injection of stem cells seems to be safe, but
only one clinical trial using MSCs via the intracoronary route in the setting of acute
myocardial infarction (AMI) has been carried out. The investigators therefore assessed the
safety and efficacy of intracoronary autologous bone marrow (BM)-derived human MSCs in
patients with AMI.